drugset / Trial / NCT04007588
A Phase II Trial of Neoadjuvant Treatment With PD-1 Inhibition (Nivolumab) With or Without IDO Inhibition (BMS-986205) and With or Without CTLA-4 Inhibition (Ipilimumab) in Resectable Stage III or IV Melanoma
RandomizedParallel-groupOpen-labelTreatment
Summary
This research study is studying different immunotherapy regimens as a possible treatment for stage III or IV resectable melanoma.
Timeline
- Start
- 2019-09-06
- Primary completion
- 2019-12-19
- Completion
- 2019-12-19
Outcome
Outcome not reported
Stopped (Enrollment): “Slow accrual”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Ipilimumab | Monoclonal antibody | — | Intravenous |
| Subject | LINRODOSTAT | Small molecule | — | Oral |
| Subject | Nivolumab | Monoclonal antibody | — | Intravenous |